- Location San Francisco, California, United States
- Date 28-06-2022 - 30-06-2022
The 4th Annual Longevity Therapeutics Summit returns to San Francisco this summer where it remains the only industry meeting uniting leading biotech/pharma drug developers, pioneering academics, and prominent investors, striving to develop effective, novel anti-aging drugs and overcome major preclinical, translational, clinical, and regulatory obstacles.
This in-person meeting will reveal the field’s cutting edge technology advancements from leading minds in the longevity community. This summit is your one-stop forum to fast-track the development of anti-aging drugs aiming to enhance healthspan, whilst uncovering the key R&D challenges limiting the development of these therapies.
With an influx of investments into the anti-aging space, 2022 is set to be a record year for research and funding in the burgeoning longevity field. Furthermore, with the FDA continuing to deny aging as an indication, a lack of robust surrogate biomarkers for aging and the high cost of running trials that measure the lifespan in humans, now is the time to come together as a community to solve the longevity community’s toughest challenges.
Join your peers from Deep Longevity, Biophytis, Elevian, Rubedo Life Sciences and many others and delve into exclusive case studies discussing cellular senescence, telomere attrition, loss of proteostasis, stem cell exhaustion, mitochondria, metabolism and more.
Leave equipped with novel ideas, actionable insights, and new connections to accelerate your progression from pipeline to clinic and develop truly curative anti-aging therapeutics.
Speakers: Anastaysia Giarletta, Principal, R42 Group, Andrei Gudkov, Chief Scientific Officer, Genome Protection, Anurag Singh, Chief Medical Officer, Amazentis, Benedetta Robilant, Chief Scientific Officer, Dorian Therapeutics, Benjamin Yaden, Senior Director, Advisor, Eli Lilly, Birgit Schilling, Associate Professor, Proteomics & Aging, Buck Institute for Research on Aging, David Furman, Associate Professor, Proteomics & Aging, Buck Artificial Intelligence Platform, Doug Ethell, Chief Executive Officer, Leucadia Therapeutics, Eric Verdin, Chief Executive Officer & President, The Buck Institute for Research on Aging, Erin Kimbrel, Vice President, Research, Astellas, John Cooke, Chief Technology Officer, Houston Methodist Academic Institute, Karl Pfleger, Angel Investor, Austin Commerical, Kate Batz, Director, Deep Knowledge Investors, Keshav K Singh, PhD Joy and Bill Harbert Endowed Chair & Professor, Heersink School of Medicine, University of Alabama at Birmingham, Louis Hawthorne, Chief Executive Officer, NaNotics, Marco Quarta, Co-Founder & Chief Executive Officer, Rubedo Life Sciences, Mark Allen, Co-Founder & Chief Executive Officer, Elevian, Michael Fossel, President, Telocyte, Michelle Keller, Senior Manager of Scientific BD, Deep Longevity Limited, Misha Shchepinov, Chief Scientific Officer, Retrotope, Nir Barzilai, Director, Einstein Institute For Aging Research, Pinchas Cohen, Dean, Leonard Davis School of Gerontology, Co-founder, CohBar, Robin Mansukhani, Chief Executive Officer, Deciduous Therapeutics, Stanislas Veillet, Chief Executive Officer, Biophytis, Viktoria Kheifets, Senior Vice President, Alkahest, William Greene, Chief Executive Officer, Fountain Therapeutics, Erik Stoops, Head of Development, ADX NeuroSciences